Evidence map›Paper›PMID 39140247›Full record

ReviewDevelopment (Cambridge, England)2024

Compensation of gene dosage on the mammalian X.

Daniela Cecalev, Beatriz Viçoso, Rafael Galupa

Abstract readReview
In one paragraph

Review in Development (Cambridge, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Sex-specific transcriptome dynamics ofGenes & development · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Sex Chromosome Evolution: Hallmarks and Question Marks.Molecular biology and evolution · 2024
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniela CecalevMolecular, Cellular and Developmental Biology (MCD) Unit, Centre de Biologie Intégrative (CBI), University of Toulouse, CNRS, UPS, 31062, Toulouse, France.ORCID 0009-0009-3854-1930
Beatriz ViçosoInstitute of Science and Technology Austria (ISTA), Am Campus 1, Klosterneuburg 3400, Austria.ORCID 0000-0002-4579-8306
Rafael GalupaMolecular, Cellular and Developmental Biology (MCD) Unit, Centre de Biologie Intégrative (CBI), University of Toulouse, CNRS, UPS, 31062, Toulouse, France.ORCID 0000-0001-7319-043X

Funding

Centre National de la Recherche ScientifiqueFondation pour la Recherche Médicale AJE202305017142Ligue Contre le Cancer LNCC_TAJT25850
6 · The paper itself

Abstract

Changes in gene dosage can have tremendous evolutionary potential (e.g. whole-genome duplications), but without compensatory mechanisms, they can also lead to gene dysregulation and pathologies. Sex chromosomes are a paradigmatic example of naturally occurring gene dosage differences and their compensation. In species with chromosome-based sex determination, individuals within the same population necessarily show 'natural' differences in gene dosage for the sex chromosomes. In this Review, we focus on the mammalian X chromosome and discuss recent new insights into the dosage-compensation mechanisms that evolved along with the emergence of sex chromosomes, namely X-inactivation and X-upregulation. We also discuss the evolution of the genetic loci and molecular players involved, as well as the regulatory diversity and potentially different requirements for dosage compensation across mammalian species.

Indexed as

Dosage Compensation, GeneticMammalsX ChromosomeX Chromosome InactivationAnimalsEvolution, MolecularGene DosageHumansDosage compensationMammalsX chromosomeX-chromosome inactivationX-chromosome upregulation

Identifiers

PMID39140247
PMCPMC11361640

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.